Latest Rosalind Advisors, Inc. Stock Portfolio
Rosalind Advisors, Inc. Performance:
2025 Q4: 10.7%YTD: 14.98%2024: 61.79%
Performance for 2025 Q4 is 10.7%, and YTD is 14.98%, and 2024 is 61.79%.
About Rosalind Advisors, Inc. and 13F Hedge Fund Stock Holdings
On 2026-02-12, the fund reported it's updated stock portfolio. In the 13F Holdings report, Rosalind Advisors, Inc. reported an equity portfolio of $284.5 Millions as of 31 Dec, 2025.
The top stock holdings of Rosalind Advisors, Inc. are DCTH, SVRA, FENC. The fund has invested 11.6% of it's portfolio in DELCATH SYSTEMS, INC. and 7.2% of portfolio in SAVARA INC.
The fund managers got completely rid off REZOLUTE INC (RZLT), VERONA PHARMA PLC (VRNA) and IDEAYA BIOSCIENCES INC (IDYA) stocks. They significantly reduced their stock positions in FRACTYL HEALTH INC, CYTOKINETICS INC (CYTK) and VIRIDIAN THERAPEUTICS INC (VRDN). Rosalind Advisors, Inc. opened new stock positions in REPLIMUNE GROUP INC (REPL) and ARRIVENT BIOPHARMA INC. The fund showed a lot of confidence in some stocks as they added substantially to X4 PHARMACEUTICALS INC (XFOR), PROFOUND MEDICAL CORP (PROF) and FENNEC PHARMACEUTICALS INC (FENC).
The top stock holdings of Rosalind Advisors, Inc. are DCTH, SVRA, FENC. The fund has invested 11.6% of it's portfolio in DELCATH SYSTEMS, INC. and 7.2% of portfolio in SAVARA INC.
The fund managers got completely rid off REZOLUTE INC (RZLT), VERONA PHARMA PLC (VRNA) and IDEAYA BIOSCIENCES INC (IDYA) stocks. They significantly reduced their stock positions in FRACTYL HEALTH INC, CYTOKINETICS INC (CYTK) and VIRIDIAN THERAPEUTICS INC (VRDN). Rosalind Advisors, Inc. opened new stock positions in REPLIMUNE GROUP INC (REPL) and ARRIVENT BIOPHARMA INC. The fund showed a lot of confidence in some stocks as they added substantially to X4 PHARMACEUTICALS INC (XFOR), PROFOUND MEDICAL CORP (PROF) and FENNEC PHARMACEUTICALS INC (FENC).
Rosalind Advisors, Inc. Annual Return Estimates Vs S&P 500
Our best estimate is that Rosalind Advisors, Inc. made a return of 10.7% in the last quarter. In trailing 12 months, it's portfolio return was 14.98%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| replimune group inc | 13,710,000 |
| arrivent biopharma inc | 4,343,320 |
| onkure therapeutics inc | 2,118,420 |
| regentis biomaterials ltd | 1,695,180 |
| neuraxis inc | 1,039,250 |
New stocks bought by Rosalind Advisors, Inc.
Additions
| Ticker | % Inc. |
|---|---|
| x4 pharmaceuticals inc | 68.71 |
| profound medical corp | 54.43 |
| fennec pharmaceuticals inc | 25.84 |
| xeris biopharma holdgs inc | 17.59 |
| cybin inc | 10.5 |
| eyepoint pharmaceuticals inc | 6.15 |
| myomo inc | 1.29 |
Additions to existing portfolio by Rosalind Advisors, Inc.
Reductions
| Ticker | % Reduced |
|---|---|
| fractyl health inc | -92.29 |
| cytokinetics inc | -51.24 |
| viridian therapeutics inc | -25.00 |
| polypid ltd | -24.18 |
| talphera inc | -18.39 |
| savara inc | -14.91 |
| verastem inc | -7.31 |
Rosalind Advisors, Inc. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| rezolute inc | -16,987,700 |
| astria therapeutics inc | -1,112,770 |
| ideaya biosciences inc | -9,523,500 |
| uniqure nv | -7,296,250 |
| verona pharma plc | -10,671,000 |
Rosalind Advisors, Inc. got rid off the above stocks
Sector Distribution
Rosalind Advisors, Inc. has about 77.7% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 77.7 |
| Others | 22.3 |
Market Cap. Distribution
Rosalind Advisors, Inc. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- SMALL-CAP
- UNALLOCATED
- MICRO-CAP
- MID-CAP
- NANO-CAP
| Category | % |
|---|---|
| SMALL-CAP | 51.4 |
| UNALLOCATED | 22.3 |
| MICRO-CAP | 13.7 |
| MID-CAP | 9.6 |
| NANO-CAP | 3 |
Stocks belong to which Index?
About 46.5% of the stocks held by Rosalind Advisors, Inc. either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 53.5 |
| RUSSELL 2000 | 46.5 |
Rosalind Advisors, Inc. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Rosalind Advisors, Inc.
Rosalind Advisors, Inc. has 29 stocks in it's portfolio. About 60.7% of the portfolio is in top 10 stocks. FENC proved to be the most loss making stock for the portfolio. SVRA was the most profitable stock for Rosalind Advisors, Inc. last quarter.
Last Reported on: 12 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRX | talphera inc | 1.43 | 3,579,270 | 4,080,370 | reduced | -18.39 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BFRI | biofrontera inc | 0.23 | 1,140,760 | 650,235 | unchanged | 0.00 | ||
| CYBN | cybin inc | 4.76 | 1,657,540 | 13,558,700 | added | 10.5 | ||
| CYTK | cytokinetics inc | 4.36 | 195,045 | 12,393,200 | reduced | -51.24 | ||
| DCTH | delcath systems, inc. | 11.60 | 3,300,390 | 33,003,900 | unchanged | 0.00 | ||
| EYPT | eyepoint pharmaceuticals inc | 4.43 | 690,000 | 12,606,300 | added | 6.15 | ||
| FENC | fennec pharmaceuticals inc | 7.07 | 2,613,510 | 20,124,000 | added | 25.84 | ||
| IDYA | ideaya biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KURA | kura oncology inc | 0.36 | 100,000 | 1,039,000 | unchanged | 0.00 | ||
| LIFE | astria therapeutics inc | 4.78 | 1,039,080 | 13,601,600 | unchanged | 0.00 | ||
| MDWD | mediwound ltd | 4.86 | 749,054 | 13,827,500 | unchanged | 0.00 | ||
| MNMD | mind medicine mindmed inc | 3.53 | 750,000 | 10,042,500 | unchanged | 0.00 | ||
| MYO | myomo inc | 1.23 | 3,839,770 | 3,494,190 | added | 1.29 | ||
| NSPR | inspiremd inc | 2.44 | 3,905,740 | 6,952,220 | unchanged | 0.00 | ||
| OCUL | ocular therapeutix, inc | 1.71 | 400,000 | 4,856,000 | unchanged | 0.00 | ||
| PROF | profound medical corp | 2.96 | 1,068,960 | 8,412,680 | added | 54.43 | ||
| PYPD | polypid ltd | 1.06 | 696,556 | 3,023,050 | reduced | -24.18 | ||
| QURE | uniqure nv | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| REPL | replimune group inc | 4.82 | 1,410,500 | 13,710,000 | new | |||